NASDAQ:TTOO - T2 Biosystems Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.58 +0.06 (+2.38 %)
(As of 04/23/2019 08:25 AM ET)
Previous Close$2.52
Today's Range$2.45 - $2.59
52-Week Range$2.45 - $9.98
Volume497,406 shs
Average Volume728,458 shs
Market Capitalization$114.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.50 million
Book Value$0.26 per share

Profitability

Net Income$-51,150,000.00
Net Margins-487.17%

Miscellaneous

Employees153
Market Cap$114.35 million
Next Earnings Date5/2/2019 (Confirmed)
OptionableOptionable

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) released its earnings results on Thursday, March, 7th. The medical equipment provider reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.04. The medical equipment provider had revenue of $1.79 million for the quarter, compared to the consensus estimate of $2.52 million. T2 Biosystems had a negative return on equity of 358.67% and a negative net margin of 487.17%. View T2 Biosystems' Earnings History.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for T2 Biosystems.

How can I listen to T2 Biosystems' earnings call?

T2 Biosystems will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8553276838.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21-21 million, compared to the consensus revenue estimate of $21.77 million.T2 Biosystems also updated its Q1 2019 guidance to EPS.

What price target have analysts set for TTOO?

6 equities research analysts have issued 1 year target prices for T2 Biosystems' stock. Their forecasts range from $5.00 to $11.00. On average, they anticipate T2 Biosystems' share price to reach $9.25 in the next year. This suggests a possible upside of 258.5% from the stock's current price. View Analyst Price Targets for T2 Biosystems.

What is the consensus analysts' recommendation for T2 Biosystems?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (3/13/2019)
  • 2. HC Wainwright analysts commented, "We have slightly lowered our 2019 revenue projection to $21M from $22M, and increased the estimates for overall operating expenses based on recent trends. Our current estimated market value of the firm has decreased to $557M from $675M. Assuming approximately 50M shares outstanding at the end of 1Q20, this translates to a per share value of approximately $11. Therefore, we reiterate our Buy rating, while reducing the 12-month price target to $11 from $14 per share." (3/8/2019)
  • 3. Canaccord Genuity analysts commented, "We’d like to provide our view and counter the key points made in the report: Point 1 – News of T2’s recent Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition, or that the device has value, only that it diagnoses life-threatening disease. Our response – This is true, but it’s still a positive. T2 just started its dialogue with the FDA on its T2Resistance panel, thus FDA has not reviewed data from T2. We believe that breakthrough device designation will (1) add more resources by the FDA on this device and (2) likely provide a speedier review process and ultimately FDA approval." (3/5/2019)
  • 4. Cantor Fitzgerald analysts commented, ": We are initiating coverage of T2 Biosystems (TTOO) with an Overweight rating and a 12-month price target of $11. We think T2’s direct-from-whole-blood species-specific technology has the potential to change the standard of care for sepsis diagnostics. T2’s diagnostic panels for bacterial and fungal infections deliver a species-specific result in 3-5 hours, compared to 2-5 days for the current standard of care. We foresee favorable emergency department economics as a gateway for hospitals to adopt T2’s technology before a broader rollout to the ICU and sepsis testing more broadly." (9/20/2018)

Has T2 Biosystems been receiving favorable news coverage?

News articles about TTOO stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. T2 Biosystems earned a news impact score of -1.6 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 5,544,868 shares, an increase of 57.3% from the March 15th total of 3,525,304 shares. Based on an average trading volume of 1,151,543 shares, the days-to-cover ratio is currently 4.8 days. Currently, 15.7% of the shares of the company are sold short. View T2 Biosystems' Current Options Chain.

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 59)
  • Prof. Michael J. Cima, Co-Founder & Director (Age 59)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)
  • Dr. Tyler E. Jacks, Co-Founder (Age 58)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different of institutional and retail investors. Top institutional investors include Bell Rock Capital LLC (0.77%), Virtu Financial LLC (0.04%) and Wiley BROS. Aintree Capital LLC (0.02%). Company insiders that own T2 Biosystems stock include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro, John Mcdonough, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.

Which major investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have sold T2 Biosystems company stock in the last year include John Mcdonough, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems.

Which major investors are buying T2 Biosystems stock?

TTOO stock was bought by a variety of institutional investors in the last quarter, including Bell Rock Capital LLC and Wiley BROS. Aintree Capital LLC. Company insiders that have bought T2 Biosystems stock in the last two years include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro and Michael Terrence Gibbs. View Insider Buying and Selling for T2 Biosystems.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $2.58.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $114.35 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is http://www.t2biosystems.com.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel